Arena Pharmaceuticals Inc. (ARNA): Today's Featured Drugs Winner

Arena Pharmaceuticals ( ARNA) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1.6%. By the end of trading, Arena Pharmaceuticals rose 35 cents (3%) to $11.81 on average volume. Throughout the day, 35 million shares of Arena Pharmaceuticals exchanged hands as compared to its average daily volume of 23.8 million shares. The stock ranged in a price between $11.46-$12.07 after having opened the day at $11.68 as compared to the previous trading day's close of $11.46. Other companies within the Drugs industry that increased today were: K-V Pharmaceutical Company ( KV.A), up 13.3%, Synageva BioPharma ( GEVA), up 10.1%, K-V Pharmaceutical Company ( KV.B), up 8.7%, and Chembio Diagnostics ( CEMI), up 7.1%.

Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena Pharmaceuticals has a market cap of $2.19 billion and is part of the health care sector. Shares are up 494.4% year to date as of the close of trading on Monday. Currently there are two analysts that rate Arena Pharmaceuticals a buy, one analyst rates it a sell, and six rate it a hold.

TheStreet Ratings rates Arena Pharmaceuticals as a sell. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity.

On the negative front, Rexahn Pharmaceuticals ( RNN), down 31%, Questcor Pharmaceuticals ( QCOR), down 21.8%, Chelsea Therapeutics International ( CHTP), down 10.5%, and Somaxon Pharmaceuticals ( SOMX), down 10.3%, were all losers within the drugs industry with Celgene Corporation ( CELG) being today's drugs industry loser.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

If you liked this article you might like

A Stampede of Buying: Cramer's 'Mad Money' Recap (Monday 9/11/17)

Allergan, USG Corp, Arena Pharmaceuticals: 'Mad Money' Lightning Round

These Stocks Have Changed Direction

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Arena Pharma Skyrockets on Heart Disease Data, Stock Could Still Double -Firm Says